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Background: Gangrenous cholecystitis (GC) is considered a more severe form of acute cholecystitis.
The risk factors associated with this condition and its impact on morbidity and mortality compared with
those of non-gangrenous acute cholecystitis (NGAC) are poorly defined and based largely on findings
from older studies.
Methods: Patients with histologically confirmed acute cholecystitis treated in specialized units in a
tertiary hospital between 2005 and 2010 were identified from a prospectively maintained database. Data
were reviewed retrospectively and patients with GC were compared with those with NGAC.
Results: A total of 184 patients with NGAC and 106 with GC were identified. The risk factors associated
with GC included older age (69 years vs. 57 years; P = 0.001), diabetes (19% vs. 10%; P = 0.049),
temperature of >38 °C (36% vs. 16%; P < 0.001), tachycardia (31% vs. 15%; P = 0.002), detection of
muscle rigidity on examination (27% vs. 12%; P = 0.01) and greater elevations in white cell count (WCC)
(13.4 ¥ 109/l vs. 10.7 ¥ 109/l; P < 0.001), C-reactive protein (CRP) (94 mg/l vs. 17 mg/l; P = 0.001), bilirubin
(19 mmol/l vs. 17 mmol/l; P = 0.029), urea (5.3 mmol/l vs. 4.7 mmol/l; P = 0.016) and creatinine (82 mmol/l
vs. 74 mmol/l; P = 0.001). The time from admission to operation in days was greater in the GC group
(median = 1 day, range: 0–14 days vs. median = 1 day, range: 0–10 days; P = 0.029). There was no overall
difference in complication rates between the GC and NGAC groups (22% vs. 14%; P = 0.102). There was
a lower incidence of common bile duct stones in the GC group (5% vs. 13%; P = 0.017). Gangrenous
cholecystitis was associated with increased mortality (4% vs. 0%; P = 0.017), but this was not an
independent risk factor on multivariate analysis.
Conclusions: Gangrenous cholecystitis has certain clinical features and associated laboratory findings
that may help to differentiate it from NGAC. It is not associated with an overall increase in complications
when treated in a specialized unit.
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Introduction
Acute cholecystitis is a common surgical problem. Gangrenous
cholecystitis (GC) is generally considered a more severe form of
acute cholecystitis.1 A number of older studies have looked at risk
factors that may distinguish GC from non-gangrenous acute
cholecystitis (NGAC) with the aim of improving outcomes by
providing more aggressive and timely treatment.2–4 Many of these
studies examined small numbers of patients in an era when early
management of acute cholecystitis was not routine.
In this study, a cohort of patients with histologically proven
acute cholecystitis were examined to determine factors predictive
of diagnoses of GC and NGAC, respectively, and to determine
factors associated with overall complications and mortality.
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Materials and methods
Acute cholecystitis was defined by a histological finding of an
acute inflammatory infiltrate on examination of the gallbladder
wall. When there was a concurrent chronic inflammatory infil-
trate, this was defined as acute-on-chronic cholecystitis. Cases
involving transmural necrosis of the gallbladder wall were defined
as GC. The condition was defined as focal if one portion of the
gallbladder wall was involved and as diffuse if more than one
portion was involved. Emergency surgery constituted surgery per-
formed in response to an acute presentation at hospital when
acute cholecystitis was first suspected. Non-emergency cases con-
sisted of patients who had been scheduled for surgery as outpa-
tients and were subsequently found to have acute cholecystitis on
histology and underwent surgery performed according to an elec-
tive operating list. In such cases, the time from hospital admission
to surgery was considered zero days. Comparisons of blood tests
used data from tests performed at the time of emergency admis-
sion or before surgery in cases of elective surgery. Length of stay
(LoS) was defined as hospital stay in days from the time of surgery
to discharge. A complication was considered as any adverse event
that required an intervention, such as re-operation, drainage or
the administration of antibiotics.
Patients
Patients treated by cholecystectomy for suspected acute cholecys-
titis between November 2005 and April 2010 within specialist
hepatobiliary and upper gastrointestinal units in a tertiary hospi-
tal were identified from a prospectively maintained database with
institutional review board approval. A retrospective analysis of
preoperative, operative and postoperative data was undertaken.
Only patients with histologically confirmed acute cholecystitis
were included.
Preoperative assessment
Demographic data including information on age, sex, American
Society of Anesthesiologists (ASA) classification, body mass index
(BMI), associated medical conditions, preoperative symptoms
and duration, time from admission to surgery, physical examina-
tion findings, blood test results and imaging results were noted.
The need for preoperative endoscopic retrograde cholangiopan-
creatography (ERCP) was recorded.
Surgical procedures
Any surgical interventions performed were documented, includ-
ing common bile duct (CBD) exploration and stenting proce-
dures. Laparoscopic surgery was the preferred mode of therapy.
Cystic duct ligation was achieved by clip application in the major-
ity of cases and EndoLoop® ligatures in the remainder. Every
possible effort was made to perform cholecystectomy at the next
available emergency time-slot once a diagnosis of suspected acute
cholecystitis had been established. Conservative management of
cholecystitis followed by delayed surgery was not practised. All
patients received intraoperative antibiotics and prophylactic
heparin, unless these were contraindicated. Records included
information on the operative technique, duration of surgery,
intraoperative complications and the seniority of the surgeon
(consultant or fellow/registrar trainee). Intraoperative cholang-
iography was performed selectively by some of the surgeons in
this study and routinely by others.
Postoperative outcome
Postoperative complications and outcomes were recorded. The
hospital LoS after surgery, including the intensive care unit (ICU)
LoS, was noted. Patients who underwent cholecystectomy and
required hospital readmissions after discharge were identified.
Follow-up was based on hospital outpatient data, physician office
records and readmission notes in cases of readmission.
Statistical analysis
Results are expressed as the median (range) unless otherwise
stated. Comparisons between categorical variables were deter-
mined using the chi-squared or Fisher’s exact test as appropriate.
Non-categorical variables were assessed by Mann–Whitney
U-test. Cox proportional analysis was undertaken to determine
factors independently associated with complications and mortal-
ity using all factors for which the P-value was <0.01 on univariate
analysis. spssVersion 16.5 (SPSS, Inc., Chicago, IL, USA) was used
for statistical analysis. A P-value of 0.05 was considered to indi-
cate statistical significance.
Results
Overall, 290 patients with histologically confirmed acute chole-
cystitis were identified. These included 106 (37%) patients with
GC and 184 (63%) patients with NGAC. Of the patients with GC,
66 (62%) had diffuse transmural necrosis and the remainder had
focal necrosis. In patients with NGAC, acute-on-chronic chole-
cystitis was noted in 95 (52%) patients and the remainder showed
histological evidence of acute cholecystitis alone.
Patient characteristics
Table 1 lists the characteristics of the patients in each group.
Patients in the GC group were more likely to be male, older and to
have diabetes. Patients presenting with GC were more likely to be
febrile, tachycardic and to exhibit muscle rigidity on examination
at presentation. There was no difference between the groups in
symptom duration prior to admission. The median time from
admission to surgery was statistically greater in the GC group, at 1
day (range: 0–14 days) vs. 1 day (range: 0–10 days) (P = 0.029).
When only emergency cases were compared, there was no statis-
tical difference in median time from admission to surgery [1 day
(range: 0–14 days) vs. 1 day (range: 0–10 days); P = 0.086].
Investigations
The laboratory and imaging findings of patients in each group are
shown in Table 1. An ultrasound diagnosis of acute cholecystitis
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Table 1 Characteristics of patients with gangrenous or non-gangrenous acute cholecystitis
Characteristics All patients
(n = 290)
Non-gangrenous acute
cholecystitis group (n = 184)
Gangrenous cholecystitis
group (n = 106)
P-value
Male, n (%) 140 (48%) 72 (39%) 68 (64%) <0.001
Age, years, median (range) 61 (18–94) 57 (19–92) 69 (18–94) 0.001
BMI, median (range) 29.5 (16.9–58.3) 28.7 (17.6–51.7) 30.0 (16.9–58.3) 0.836
ASA class, n (%) 0.076
I 54 (18%) 38 (21%) 16 (15%)
II 158 (55%) 105 (57%) 53 (50%)
III 72 (25%) 39 (21%) 33 (31%)
IV 6 (2%) 2 (1%) 4 (4%)
Comorbidity, n (%)
Ischaemic heart disease 40 (14%) 21 (11%) 19 (18%) 0.121
Chronic renal failure 23 (8%) 14 (8%) 9 (9%) 0.789
Diabetes 39 (13%) 19 (10%) 20 (19%) 0.040
Chronic liver disease 10 (3%) 7 (4%) 3 (3%) 0.751
COAD 18 (6%) 11 (6%) 7 (7%) 0.832
Upper abdominal surgery 11 (4%) 7 (4%) 4 (4%) 1.000
Smoker, n (%) 61 (25%) 43 (27%) 18 (20%) 0.214
Glucosteroid use, n (%) 6 (2%) 3 (2%) 3 (3%) 0.673
Prior biliary colic, n (%) 141 (53%) 95 (56%) 46 (48%) 0.193
Emergency department referral, n (%) 260 (90%) 165 (90%) 95 (90%) 0.989
Duration, days, median (range)
Symptoms to admission 1 (0–150) 1 (0–60) 1 (0–150) 0.115
Admission to surgery 1 (0–14) 1 (0–10) 1 (0–14) 0.029
Vital signs at presentation, n (%)
Fever (>38 °C) 67 (23%) 29 (16%) 38 (36%) <0.001
Tachycardia (HR > 100 bpm) 61 (21%) 28 (15%) 33 (31%) 0.001
Hypotension (BP < 100 mmHg) 19 (7%) 8 (4%) 11 (10%) 0.046
Findings at presentation, n (%)
Muscular rigidity 51 (18%) 22 (12%) 29 (27%) 0.001
Murphy's sign positive 160 (57%) 94 (54%) 66 (62%) 0.161
Laboratory tests, median (range)
Haemoglobin, g/l 140 (90–182) 140 (90–182) 143 (100–171) 0.313
White cell count, ¥109/l 11.7 (1.4–32.4) 10.7 (3.7–32.4) 13.4 (1.4–29.0) <0.001
Platelets, ¥109/l 274 (73–893) 281 (73–893) 266 (69–528) 0.079
CRP, mg/l 23 (0–500) 17 (1.0–380) 94 (0–500) 0.001
Bilirubin, mmol/l 18 (5–152) 17 (5–152) 19 (8–148) 0.029
ALT, U/l 36 (6–1381) 43 (6–1381) 26 (10–705) <0.001
ALP, U/l 83 (28–487) 85 (36–487) 79 (28–234) 0.061
GGT, U/l 41 (8–1290) 50 (8–1290) 30 (8–666) <0.001
Albumin, g/l 39 (19–72) 39 (19–49) 39 (20–72) 0.552
Amylase, U/l 67 (15–3286) 64 (15–3286) 72 (25–615) 0.158
Lipase, U/l 24 (10–4270) 24 (10–4270) 25 (12–106) 0.443
Urea, mmol/l 4.9 (1.5–73) 4.7 (1.5–73) 5.3 (1.5–29.8) 0.016
Creatinine, mmol/l 77 (49–1070) 74 (49–394) 82 (49–1070) 0.001
Bicarbonate, mmol/l 26 (17–62) 26 (17–62) 26 (17–34) 0.597
Blood culture positive 10 (3%) 6 (3%) 4 (4%) 1.000
Radiological investigations, n (%)
Ultrasound
Diagnosis of acute cholecystitis 195 (71%) 113 (65%) 82 (80%) 0.012
Gallbladder wall thickening 189 (69%) 109 (64%) 80 (76%) 0.031
Pericholecystic fluid 81 (29%) 46 (26%) 35 (33%) 0.188
CBD diameter, mm, median (range) 6 (1.2–15.0) 6 (2.0–15.0) 6 (1.2–12.0) 0.557
CT diagnostic of cholecystitis, n (%) 39 (13%) 24 (13%) 15 (14%) 0.790
MRCP diagnostic of cholecystitis, n (%) 8 (3%) 4 (2%) 4 (4%) 0.471
BMI, body mass index; ASA, American Society of Anaesthesiologists; COAD, chronic obstructive airways disease; HR, heart rate; BP, blood pressure; CRP, C-reactive protein; ALT, alanine
transaminase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; CBD, common bile duct; CT, computed tomography; MRCP, magnetic resonance cholangiopancreatography.
Missing values: BMI, n = 188; smoker, n = 41; glucosteroid use, n = 3; biliary colic history, n = 25; muscle rigidity, n = 1; Murphy's sign positive, n = 9; haemoglobin, n = 2; platelets,
n = 3; white cell count, n = 3; CRP, n = 94; bilirubin, n = 5; ALT, n = 8; ALP, n = 5; albumin, n = 6; GGT, n = 6; amylase, n = 235; lipase n = 57; urea, n = 1; creatinine, n = 1; CBD diameter,
n = 15; gallbladder thickening, n = 14; pericholecystic fluid, n = 8; MRCP status, n = 1; duration of surgery, n = 1.
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was more common in the GC group than in the NGAC group (as
was the finding of gallbladder wall thickening). Patients in the GC
group had greater elevations in white cell count, C-reactive
protein (CRP) level, bilirubin, urea and creatinine. Patients with
NGAC had greater elevations at presentation in alanine transami-
nase (ALT) and gamma-glutamyl transferase (GGT) levels. Seven
patients (2%) were diagnosed with pancreatitis preoperatively. All
were in the NGAC group.
Operative details
Operative details are noted in Table 2. Overall, 94% of patients in
this series had emergency hospital admissions and surgery. This
was more frequent in the GC group (98% vs. 91%; P = 0.021).
Patients in the GC group were also more likely than those in the
NGAC group to receive preoperative antibiotics at presentation
(94% vs. 80%; P = 0.001). A total of 27 (9%) patients required
ERCP prior to surgery for treatment of CBD stones. Most patients
(88%) were treated by laparoscopic cholecystectomy. There were
no differences between the groups in the percentage of patients
undergoing laparoscopic surgery or the percentage of patients
requiring conversion to open surgery. A consultant surgeon was
more likely to be scrubbed in for patients in the GC group.
Overall, 60% of patients underwent intraoperative cholangiogra-
phy and rates did not differ between the groups. Common bile
duct stones were noted in 31 (11%) cases at the time of surgery;
the incidence of CBD stones did not differ between the groups.
Drain tubes were more commonly utilized in the GC group.
Postoperative details
Postoperative details and complications are noted in Table 3.
Overall complication rates were similar between the groups. Chest
infection, cardiac complications and bile leak were the most
common complications noted. However, patients in the GC group
were more likely to require ICU admission postoperatively (15%
vs. 7%; P = 0.017). Four deaths occurred in this series, all of which
referred to patients in the GC group (4% vs. 0%; P = 0.017). The
median postoperative LoS was greater in the GC than the NGAC
group at 4 days (range: 0–17 days) vs. 3 days (range: 1–33 days)
(P = 0.005). Rates of postoperative readmission and need for
ERCP did not differ between groups. Four (1%) patients demon-
strated retained bile duct stones; three of these underwent intra-
operative cholangiography. The presence of CBD stones was
noted in 60 (21%) patients and included stones detected during
the pre-, intra- and postoperative periods. The incidence of CBD
stones was greater in the NGAC (n = 46, 25%) than the GC (n =
14, 13%) group (P = 0.023).
Table 2 Comparison of operative data in patients with gangrenous and non-gangrenous acute cholecystitis
All patients
(n = 290)
Non-gangrenous
acute cholecystitis
group (n = 184)
Gangrenous
cholecystitis
group (n = 106)
P-value
Preoperative management, n (%)
Preoperative ICU 9 (3%) 6 (3%) 3 (3%) 1.000
Preoperative ERCP 27 (9%) 22 (12%) 5 (5%) 0.090
Preoperative antibiotics 247 (85%) 147 (80%) 100 (94%) 0.001
Operation, n (%)
Emergency surgery 272 (94%) 168 (91%) 104 (98%) 0.021
Laparoscopic surgery 254 (88%) 163 (89%) 91 (86%) 0.496
Open surgery 9 (3%) 8 (4%) 1 (1%) 0.162
Conversion to open surgery 27 (10%) 13 (7%) 14 (14%) 0.096
Drain tube in situ 198 (68%) 112 (61%) 86 (81%) <0.001
IOC, n (%)
IOC performed 175 (60%) 116 (63%) 59 (56%) 0.216
IOC detected stones 31 (11%) 21 (11%) 10 (9%) 0.599
Operative time, min, median (range) 100 (25–360) 100 (25–360) 105 (35–210) 0.401
Surgeon, n (%)
Consultant surgeon scrubbed 150 (52%) 87 (47%) 63 (59%) 0.046
Extra procedure, n (%)
Transpapillary stent 7 (2%) 3 (2%) 4 (4%) 0.429
Gallstones present at pathology examination, n (%)
No gallstones identified 50 (18%) 30 (17%) 20 (19%) 0.682
Single gallstone 57 (20%) 36 (20%) 21 (20%) 0.959
ICU, intensive care unit; ERCP, endoscopic retrograde cholangiopancreatography; IOC, intraoperative cholangiogram.
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Complications
Factors with significant or trending towards significant influence
on complications are noted in Table 4. There was an overall non-
significant trend towards increased complications in the GC
group. On multivariate analysis, age >70 years [odds ratio (OR)
2.9, 95% confidence interval (CI) 1.1–7.6; P = 0.029], diabetes
(OR 3.9, 95% CI 1.4–11.2; P = 0.012) and the presence of muscle
rigidity on initial examination (OR 2.7, 95% CI 1.0–6.9; P = 0.042)
were the only independent factors associated with increased
complications.
Mortality
Factors with significant or trending towards significant influence
on mortality are noted in Table 5. A diagnosis of GC, age >70
years, ischaemic heart disease, diabetes, muscle rigidity at presen-
tation, presence of pericholecystic fluid on ultrasound, creatinine
>90 mmol/l and urea >6 mmol/l were associated with increased
mortality on univariate analysis. However, multivariate analysis
did not identify any independent predictors of mortality.
Discussion
Gangrenous cholecystitis is considered a more severe form of
acute cholecystitis. It is primarily caused by vascular compromise
secondary to epithelial injury caused by sustained obstruction of
the cystic duct.5 As a result of the epithelial injury, phospholipases
that degrade adjacent cell membranes are released, leading to an
intense inflammatory reaction. The combination of gallbladder
wall tension and the intense inflammatory reaction results in
either local or global gallbladder wall ischaemia. The exact time
courses of such events are unknown. It has been suggested that it
may take days for such a progression to occur, although several
reports indicate that the progression is far more rapid.2,6,7
Gangrenous cholecystitis has been reported to occur in 10–40%
of all patients presenting with acute cholecystitis.2,4 In the current
series, GC occurred in 37% of all patients with acute cholecystitis.
This figure is in keeping with those reported by other studies that
used a histological criterion to define acute cholecystitis.2 In this
series, patients with focal transmural necrosis of the gallbladder or
diffuse necrosis were considered to have GC. Whether other series
with lower reported incidences of GC excluded some cases of focal
necrosis is unknown. The spectrum of patients presenting with
acute cholecystitis might be expected to have changed in recent
years as patients with biliary type symptoms are now treated
earlier, prior to the development of complications. However, in
this series about half of all patients with GC or NGAC had a
history of preceding biliary symptoms, a figure that has not
changed from those reported in older series.8
A number of differences between patients with GC and NGAC
have been noted in other studies. These include differences in the
presence of leukocytosis, age, diabetes and delay in operation.1–4
Disturbances in liver function tests have also been reported.2,3 In
the current study, differences were noted in patient characteristics,
examination findings, laboratory tests and radiological results.
Patients with GC were more likely to be male, older, to have
diabetes, to be febrile, and to display an elevated pulse and muscle
rigidity on examination. Ultrasonography was more likely to
demonstrate thickening of the gallbladder wall and a diagnosis of
Table 3 Comparison of postoperative data in patients with gangrenous and non-gangrenous acute cholecystitis
All patients
(n = 290)
Non-gangrenous acute
cholecystitis group
(n = 184)
Gangrenous
cholecystitis
group (n = 106)
P-value
Length of stay, days, median (range) 4 (0–33) 3 (1–33) 4 (0–17) 0.005
Complication, n (%)
Postoperative complication 49 (17%) 26 (14%) 23 (22%) 0.102
Wound infection 5 (2%) 2 (1%) 3 (3%)
Intraoperative collection 2 (1%) 2 (1%) 0 (0%)
Bile leak 7 (2%) 5 (3%) 2 (2%)
Retained stone 4 (1%) 3 (2%) 1 (1%)
Chest infection 10 (3%) 4 (2%) 6 (6%)
Cardiac 10 (3%) 4 (2%) 6 (6%)
Urinary retention 3 (1%) 1 (1%) 2 (2%)
Other 13 (6%) 7 (4%) 6 (6%)
Follow-up, n (%)
Unplanned HDU/ICU stay 28 (10%) 12 (7%) 16 (15%) 0.017
Readmission 11 (4%) 7 (4%) 4 (4%) 1.000
Postoperative ERCP 16 (6%) 12 (7%) 4 (4%) 0.427
Death within 90 days 4 (1%) 0 (0%) 4 (4%) 0.017
HDU, high-dependency unit; ICU, intensive care unit; ERCP, endoscopic retrograde cholangiopancreatography.
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Table 4 Factors influencing complications (of significant or trending towards significant influence)
No postoperative
complication
(n = 241)
With postoperative
complication
(n = 49)
OR (95% CI) P-value
Histopathology, n (%)
Gangrenous cholecystitis 83 (35%) 23 (47%) 1.7 (0.9–3.1) 0.098
Demographic, n (%)
Age > 70 years 77 (32%) 34 (69%) 4.8 (2.5–9.4) <0.001
Comorbidity, n (%)
Ischaemic heart disease 29 (12%) 11 (22%) 2.1 (1.0–4.6) 0.054
Chronic renal failure 14 (6%) 9 (18%) 3.6 (1.5–9.0) 0.003
Diabetes 23 (10%) 16 (33%) 4.6 (2.2–9.6) <0.001
COAD 10 (4%) 8 (16%) 4.5 (1.7–12.1) 0.001
Smoker 56 (27%) 5 (10%) 0.3 (0.1–0.9) 0.026
Glucosteroid use 3 (1%) 3 (6%) 5.1 (1.0–26.1) 0.030
Fever (>38 °C) 49 (20%) 18 (37%) 2.3 (1.2–4.4) 0.016
Hypotension (BP < 100 mmHg) 13 (5%) 6 (12%) 2.5 (0.9–6.8) 0.077
Muscle rigidity 35 (15%) 16 (33%) 2.8 (1.4–5.7) 0.002
ASA class, n (%) N/A <0.001
I 50 (20.8%) 4 (8.2%)
II 140 (58.3%) 17 (34.7%)
III 46 (19.2%) 26 (53.1%)
IV 4 (1.7%) 2 (4.1%)
Haemoglobin < 130 g/l, n (%) 46 (19%) 17 (35%) 2.3 (1.2–4.5) 0.013
Albumin < 35 g/l, n (%) 47 (20%) 17 (36%) 2.3 (1.2–4.5) 0.014
Creatinine > 90 mmol/l, n (%) 67 (28%) 21 (43%) 1.9 (1.0–3.7) 0.033
Urea > 6 mmol/l, n (%) 61 (25%) 24 (49%) 2.8 (1.5–5.3) 0.001
OR, odds ratio; 95% CI, 95% confidence interval; COAD, chronic obstructive airway disease; BP, blood pressure; ASA, American Society of
Anesthesiologists; N/A, not applicable.
Missing values: smoker, n = 41; steroid use, n = 3; muscle rigidity, n = 1; haemoglobin, n = 2; albumin, n = 6; urea, n = 1; creatinine, n = 1.
Table 5 Factors influencing mortality (of significant or trending towards significant influence)
Alive at 90 days
(n = 286)
Death within
90 days (n = 4)
OR (95% CI) P-value
Histopathology, n (%)
Gangrenous cholecystitis 102 (35.7%) 4 (100%) 2.8 (2.4–3.3) 0.017
Demographic, n (%)
Age > 70 years 107 (37.4%) 4 (100%) 2.7 (2.3–3.1) 0.021
Comorbidity, n (%)
Ischaemic heart disease 37 (12.9%) 3 (75%) 20.2 (2.1–199.0) 0.009
Diabetes 36 (12.6%) 3 (75.0%) 20.8 (2.1–205.7) 0.008
Examination findings, n (%)
Muscle rigidity 48 (16.8%) 3 (75%) 14.8 (1.5–145.5) 0.018
Investigations, n (%)
Pericholecystic fluid 78 (28.1%) 3 (75%) 7.7 (0.8–75.1) 0.039
White cell count > 13.5 ¥ 109/l 91 (31.9%) 3 (75%) 6.4 (0.7–62.3) 0.103
Creatinine > 90 mmol/l 84 (29.4%) 4 (100%) 3.4 (2.8–4.1) 0.008
Urea > 6 mmol/l 81 (28.4%) 4 (100%) 3.5 (2.9–4.2) 0.007
OR, odds ratio; 95% CI, 95% confidence interval.
Missing values: muscle rigidity, n = 1; urea, n = 1; creatinine, n = 1.
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acute cholecystitis in the GC group, although there are no well-
defined preoperative predictors on ultrasound specifically for
GC.9 Greater elevations in white cell count, CRP, bilirubin, urea
and creatinine were also noted in the GC group. Despite these
observed differences, it should be remembered that the clinical
presentation, laboratory and imaging findings in GC can be indis-
tinguishable from those in NGAC.
Greater delays to surgery have been noted in GC patients
reported by others.1–4 Although there was a statistically significant
difference between groups in the time between hospital admission
and surgery in our series, the difference did not appear to be
clinically significant and the median time to surgery from admis-
sion was the same in both groups. When elective surgery cases
were excluded from analysis in the current series, no statistically
significant difference between the groups was noted. There was no
difference in symptom duration prior to presentation in this
series, suggesting that the development of GC may not simply
represent a progression in the severity of acute cholecystitis. Pre-
vious studies have shown clinically significant delays in presenta-
tion and time to operation in patients with GC.1 One reason cited
by others for such delays concerns the finding that GC is more
common in elderly subjects, in whom a classic clinical presenta-
tion of acute cholecystitis is less frequent.10
An unexpected finding in this series concerned the high rate of
detection of CBD stones. The overall incidence of CBD stones was
21%. Incidences of CBD stones in the NGAC and GC groups
were 25% and 13%, respectively. Approximately half the stones
were detected and treated preoperatively. A similar number were
detected intraoperatively, although only 60% of all patients
underwent intraoperative cholangiography as a result of the selec-
tive cholangiography policy applied by some surgeons in this
study. The CBD stone rate in this series is higher than that
reported in uncomplicated cholelithiasis.11 This would support
routine imaging of the bile duct in such cases.
When factors contributing to complications in this series were
analysed, no significant difference between the groups emerged
in terms of morbidity. The overall bile leak rate was 2% without
associated major bile duct injury. When the various factors asso-
ciated with morbidity were assessed by multivariate analysis, age
>70 years, diabetes and the presence of muscle rigidity on initial
examination were found to be the only independent risk factors
for increased morbidity. Others have identified age and diabetes
as risk factors, but the presence of muscle rigidity has not been
analysed as far as we are aware.1–4 Previous studies have reported
increased abscess formation, perforations, biliary peritonitis,
increased conversion to open surgery and prolonged hospital
stay with GC.1–4,7 In our series GC was not associated with
increased complications. We speculate that this may relate to a
policy of early surgery when acute cholecystitis is clinically sus-
pected and the fact that all cases are managed in specialized sur-
gical units. The medical management of acute cholecystitis,
particularly in cases of GC, is associated with a very high failure
rate in older studies.10 Early cholecystectomy as opposed to
initial conservative therapy is supported by the findings of
several recent studies.12,13
Mortality in this series occurred only in the GC group and no
incidents of mortality were directly related to surgery. Several
other factors were identified on univariate analysis as being asso-
ciated with mortality. When these factors were analysed by mul-
tivariate analysis, none were independently associated with
increased mortality. The small number of deaths in this series
may be one reason why independent risk factors could not be
identified.
Conclusions
Gangrenous cholecystitis accounts for approximately one third of
all cases of acute cholecystitis. Patients with GC are more likely to
be older, to be male, to have diabetes and to present with fever,
tachycardia or abdominal rigidity on examination. Morbidity
associated with the treatment of GC does not significantly differ
from that related to NGAC when operative treatment within spe-
cialized units is offered soon after the clinical suspicion of acute
cholecystitis is identified. Age, diabetes and identification of
muscle rigidity on examination were the only independent factors
affecting morbidity. Although GC was associated with increased
mortality, this did not appear to be an independent risk factor.
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